Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists

October 2019 | Volume 18 | Issue 10 | Original Article | 980 | Copyright © October 2019


Rebeca Teplitz BA,ª Giselle Prado MD,B Graham H. Litchman DO MS,B Darrell S. Rigel MD MSc

ªMedical Student, New York Institute of Technology, College of Osteopathic Medicine, Old Westbury, NY

BClinical Research Fellow, National Society for Cutaneous Medicine, New York, NY

cClinical Professor, Department of Dermatology, NYU School of Medicine, New York, NY



notherapy by dermatologists in 2 of 3 vignettes. (Table 3) For all vignettes with a Class 2 cSCC-GEP test result, there was a statistically significant increase in adjuvant chemotherapy or immunotherapy recommendations.

Impact of cSCC-GEP Test Results on Decision to Refer for SLNBx
A Class 1 cSCC-GEP test result led to a statistically significant decrease in the proportion of SLNBx recommended by dermatologists in 2 of 3 vignettes. (Table 3) For all vignettes with a Class 2 cSCC-GEP test result, there was a statistically significant increase in SLNBx recommendations.

Impact of cSCC-GEP Test Results on Recommended Follow-up Interval
A Class 1 cSCC-GEP result led to a statistically significant increase in the number of respondents who would recommend

Close Menu